DECODING THE ROLE OF PROBIOTICS IN INFANT HEALTH: INSIGHTS FROM CLINICAL AND EXPERIMENTAL EVIDENCE

Abstract

Infancy is a critical time for the inception of gut microbiota, which is essential for long- term development, immunological maturation, and infant health. Probiotic therapies have been clinically proven to promote digestive health and defense against dysbiosis-related illnesses by regulating microbial composition, elevating microbial diversity, and lowering possibly pathogenic bacteria, particularly with strains like bifidobacterium and lactobacillus. Probiotics can strengthen gastrointestinal function, ease constipation, minimize the risk of infections, and reduce the frequency of acute necrotizing enterocolitics (NEC) in premature newborns, based on clinical findings. Additionally, probiotics, prebiotics, and synbiotics have been related to reduce prevalence of atopic dermatitis, and allergic sensitization during pregnancy and early life period, emphasizing their role in immunological programming. Despite outcomes in human, are still inconclusive, emerging findings also highlight potential gains on cognitive and neurodevelopmental results via regulation of gut-brain exist. In conclusion, additionally probiotics, synbiotics, or human milk oligosaccharides (HMOs) to baby formulae has confirmed potential for encouraging balanced gut colonization and partially mimicking the protective advantages of breastfeeding. Overall, these outcomes emphasize the diverse effects of probiotics across early life stages, covering gut health, immunology, prevention of allergic conditions, cognitive maturation, and nutritional support, establishing them crucial tactic for enhancing early-life health outcomes.